FDA 483 - Steri-Pharma, LLC - October 04, 2022

An FDA inspection of Steri-Pharma, LLC, a sterile drug manufacturer in Syracuse, NY, revealed significant deficiencies in laboratory controls and equipment calibration. The firm failed to follow and document established test procedures for growth promotion and did not adequately calibrate temperature monitoring equipment. These issues indicate a lack of control over critical manufacturing and testing processes.